Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Non-cash Items: 2014-2024

  • Ocular Therapeutix's Non-cash Items rose 239.46% to $11.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $11.4 million, marking a year-over-year increase of 239.46%. This contributed to the annual value of $11.4 million for FY2024, which is 3.13% up from last year.
  • Latest data reveals that Ocular Therapeutix reported Non-cash Items of $11.4 million as of Q4 2024, which was up 239.46% from $3.4 million recorded in Q4 2023.
  • In the past 5 years, Ocular Therapeutix's Non-cash Items ranged from a high of $16.1 million in Q4 2020 and a low of $7,000 during Q4 2022.
  • For the 3-year period, Ocular Therapeutix's Non-cash Items averaged around $4.9 million, with its median value being $3.4 million (2023).
  • As far as peak fluctuations go, Ocular Therapeutix's Non-cash Items crashed by 99.95% in 2022, and later skyrocketed by 47,957.14% in 2023.
  • Over the past 5 years, Ocular Therapeutix's Non-cash Items (Quarterly) stood at $16.1 million in 2020, then dropped by 17.37% to $13.3 million in 2021, then plummeted by 99.95% to $7,000 in 2022, then surged by 47,957.14% to $3.4 million in 2023, then spiked by 239.46% to $11.4 million in 2024.
  • Its Non-cash Items stands at $11.4 million for Q4 2024, versus $3.4 million for Q4 2023 and $7,000 for Q4 2022.